Skip to main content
Premium Trial:

Request an Annual Quote

Theranostics Licenses Biomarker Microdissection Tech from NIH

NEW YORK (GenomeWeb News) – Theranostics Health said today it has licensed proteomic biomarker discovery technology from the National Institutes of Health that was developed by the company’s founders.
 
The Rockville, Md.-based company’s core technology, Reverse Phase Protein Microarray combined with Laser Capture Microdissection, was developed by company co-founders Emanuel Petricoin and Lance Liotta.
 
Under the agreement, Theranostics will pay NIH license issue royalties, minimum annual royalties, and benchmark and earned royalties upon successful commercialization of the technology.
 
Petricoin, CSO of Theranostics, said in a statement that the company's “unique signaling pathway platform allows the activity of theranostic biomarkers of interest to be quantitatively measured from microdissected patient samples.”
 
Theranostics Health CEO Danong Chen said the exclusive license allows the company to develop companion diagnostics to be used in treatment decision-making and monitoring.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.